Latest Small molecule Stories
Simulations by UC Santa Barbara researchers improve understanding of plaque formation and suggest new diagnostic and treatment options Alzheimer's disease is one of the most dreaded and debilitating illnesses one can develop. Currently, the disease afflicts 6.5 million Americans and the Alzheimer's Association projects it to increase to between 11 and 16 million, or 1 in 85 people, by 2050. Cell death in the brain causes one to grow forgetful, confused and, eventually, catatonic....
RESEARCH TRIANGLE PARK, N.C., June 14, 2012 /PRNewswire/ -- TeraDiscoveries, Inc., announced today the identification of the first six biological targets for which the company is designing new drug candidates. This development follows the formation of a strategic relationship TeraDiscoveries has established with Microsoft Corp. Microsoft is providing support and cloud computing time on Windows Azure that TeraDiscoveries is applying to identify inhibitors of 25 top biological...
A small molecule developed at the Weizmann Institute prevents a cancer-causing message from entering the cell nucleus What’s good news in one setting might spell disaster in another. In cancer for instance, when a certain cell is commanded to grow and divide without restraint, it’s a welcome message for the cell itself but a tragedy for the person who harbors this cell in his or her body. Weizmann Institute scientists have managed to decipher and block one type of molecular message...
Connie K. Ho for redOrbit.com Novemdecillion – now that’s a huge number. A report published in the American Chemical Society journal Chemical Neuroscience estimates that scientists have barely synthesized one tenth of one percent of the possible medicines that could be made. The estimate of these “small molecules” is potentially 1 novemdecillion, which equals a one with 60 zeros or 1 million billion billion billion billion billion billion. The American Chemical Society is a...
BOULDER, Colo., April 30, 2012 /PRNewswire/ -- BiOptix today announced participation in the 8th Annual PEGS: Protein Engineering Summit, to be held in Boston April 30 - May 4, 2012. Supporting PEGS allows BiOptix to showcase a growing family of Enhanced Surface Plasmon Resonance Instrumentation, highlighting the BiOptix 104sa and the forthcoming BiOptix 404pi. "Participation in PEGS is a valuable opportunity for us to connect to our core customer," noted Ken Wilczek, Vice...
BOULDER, Colo., April 26, 2012 /PRNewswire/ -- BiOptix today formally unveiled a new corporate brand identity and tag line: "Kinetics with Confidence," which is designed to promote the company's mission to transform how scientists perform label free kinetic analysis on proteins, nucleic acids and small molecules. "BiOptix is rapidly expanding, and we needed a brand and corporate identity that reflects the aspirations of the company as well as communicates our value proposition to...
Glowing 'Spinach' produces a snapshot of abnormal molecules inside diseased cells, providing clues about how to treat disorders By engineering cells to express a modified RNA called "Spinach," researchers have imaged small-molecule metabolites in living cells and observed how their levels change over time. Metabolites are the products of individual cell metabolism. The ability to measure their rate of production could be used to recognize a cell gone metabolically awry, as in cancer, or...
PALO ALTO, Calif., Feb. 8, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that CEO Michael M. Wick, M.D., Ph.D. will provide a corporate overview at the 14(th) Annual BIO CEO & Investor Conference in New York City on Tuesday, February 14 at 1:00 p.m. Eastern time (10:00 a.m. Pacific time), in the Waldorf-Astoria Hotel's Conrad Suite. A live and archived webcast of the presentation will be available on the Telik website, www.telik.com. The archived broadcast of...
Efficient, economical molecule could speed evaluation of some anti-cancer treatments Researchers from Boston College have developed a new class of small molecule receptors capable of detecting a lipid molecule that reveals the telltale signs of cellular death, particularly cancer cells targeted by anti-cancer drugs, the team reports in the current electronic edition of the Journal of the American Chemical Society. Researchers led by Assistant Professor of Chemistry Jianmin Gao...
ANSONIA, Conn., Sept. 12, 2011 /PRNewswire/ -- Arrien Pharmaceuticals LLC (Arrien) is a new start-up Company located in the Connecticut & Salt Lake City area announces today of its successful completion of Series A financing from contributions by the founders of the company and currently engaged in the discovery and development of breakthrough novel small molecules targeting cell signalling pathways. Arrien developed a proprietary platform - Fragment-Field Drug Design (FFDD(TM))...
